Serum S100B, Lactate Dehydrogenase and Brain Metastasis Are Prognostic Factors in Patients with Distant Melanoma Metastasis and Systemic Therapy

Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis

(2012) B Weide et al.   BRITISH JOURNAL OF CANCER

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma

(2011) Friederike Egberts et al.   EUROPEAN JOURNAL OF CANCER

Does metastasectomy improve survival in patients with stage IV melanoma? a cancer registry analysis of outcomes

(2011) Nabil Wasif et al.   JOURNAL OF SURGICAL ONCOLOGY

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Predicting Survival Outcome of Localized Melanoma: An Electronic Prediction Tool Based on the AJCC Melanoma Database

(2010) Seng-jaw Soong et al.   ANNALS OF SURGICAL ONCOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Elevated serum levels of the glial marker protein S100B are not specific for schizophrenia or mood disorders

(2009) M L Schroeter et al.   MOLECULAR PSYCHIATRY

Long-Term Survival Analysis in Metastatic Melanoma: Serum S100B Is an Independent Prognostic Marker and Superior to LDH

(2008) Friederike Egberts et al.   ONKOLOGIE